Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.

Blood - 22 Oct 2009

Malcovati Luca, Della Porta Matteo G, Pietra Daniela, Boveri Emanuela, Pellagatti Andrea, Gallì Anna, Travaglino Erica, Brisci Angela, Rumi Elisa, Passamonti Francesco, Invernizzi Rosangela, Cremonesi Laura, Boultwood Jacqueline, Wainscoat James S, Hellström-Lindberg Eva, Cazzola Mario

Abstract excerpt

We studied patients with myeloid neoplasm associated with ringed sideroblasts and/or thrombocytosis. The combination of ringed sideroblasts 15% or greater and platelet count of 450 x 10(9)/L or greater was found in 19 subjects fulfilling the diagnostic criteria for refractory anemia with ringed sideroblasts (RARS) associated with marked thrombocytosis (RARS-T), and in 3 patients with primary myelofibrosis. JAK2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to Granulocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Platelet Count

Share to Receptors, Thrombopoietin

Share to T-Lymphocytes

Share to Thrombocytosis

Share to X Chromosome Inactivation

Source

Identifiers

PMID: 19692701
DOI: 10.1182/blood-2009-05-222331

Genes

JAK2
MPL
ABCB7
ALAS2
CXCR4
PSIP1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.PMID 19692701Read ↗

Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings.Semantic proximity Read ↗

Refractory anemia with ring sideroblasts and RARS with thrombocytosis.Semantic proximity Read ↗

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic featuresSemantic proximity Read ↗

Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.Semantic proximity Read ↗

Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?Semantic proximity Read ↗

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.Semantic proximity Read ↗

Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.Semantic proximity Read ↗

Refractory anemia with ring sideroblasts.Semantic proximity Read ↗

Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.Semantic proximity Read ↗

Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutationsSemantic proximity Read ↗

Clinical Application for Diagnosis of Myelodysplatic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.